Efficacy of the additional effect of LTRA to the asthmatics who has taken both ICS and LABA.

Efficacy of the additional effect of LTRA to the asthmatics who has taken both ICS and LABA. - Efficacy of the additional effect of LTRA to the asthmatics who has taken both ICS and LABA.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002367

Enrollment

Registered

2009-08-21

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchial asthma

Interventions

inhalation corticosteroid + long-acting beta-2 agonist as treatment continues for eight weeks. 10mg of montelukast sodium added for inhalation corticosteroid + long-acting beta-2 agonist as treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patient to whom ICS 200-400 microgram (FP conversion) is administered. 2)Patient to whom LABA is administered. 3)The patient according to ACT who is not Total control though it is Well control. 4)Patient who was able to acquire agreement by document.

Exclusion criteria

Exclusion criteria: 1)Patient who has previous history of side effect or hypersensitivity serious compared with element of research medicine 2)Patient judged to be improper according to doctor when targeting it

Design outcomes

Primary

Measure	Time frame
Amount of change of ACT number (for four weeks)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026